Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Dougados, Maxime" or (type any "bookEditor issueEditor" and editor="Dougados, Maxime")

Add to list
- Journal Article
- A1
- open access
Response to : 'Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis : results of the open-label, pragmatic, cluster-randomised TICOSPA trial' by Cai and Peng response

Anna Molto, Desiree van der Heijde, Filip Van den Bosch (UGent) and Maxime Dougados

(2023) ANNALS OF THE RHEUMATIC DISEASES. 82(7).
Add to list
- Miscellaneous
Goodbye to the term ‘ankylosing spondylitis’, hello ‘axial spondyloarthritis’: time to embrace the ASAS-defined nomenclature

Désirée van der Heijde, Anna Molto, Sofia Ramiro, Jürgen Braun, Maxime Dougados, Floris A van Gaalen, Lianne S Gensler, Robert D Inman, Robert B M Landewé, Helena Marzo-Ortega, et al.

(2023) Annals of the Rheumatic Diseases. p.ard-2023
Add to list
- Journal Article
- A1
- open access
Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis : a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR

Walter P. Maksymowych, Pascal Claudepierre, Manouk de Hooge (UGent) , Robert G. Lambert, Robert Landewé, Anna Molto, Désirée van der Heijde, Jack F. Bukowski, Heather Jones, Ron Pedersen, et al.

(2021) ARTHRITIS RESEARCH & THERAPY. 23(1).
Add to list
- Journal Article
- A1
- open access
Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis : results of the open-label, pragmatic, cluster-randomised TICOSPA trial

Anna Molto, Clementina López-Medina, Filip Van den Bosch (UGent) , Annelies Boonen, Casper Webers, Emanuelle Dernis, Floris A van Gaalen, Martin Soubrier, Pascal Claudepierre, Athan Baillet, et al.

(2021) ANNALS OF THE RHEUMATIC DISEASES. 80(11). p.1436-1444
Add to list
- Journal Article
- A1
- open access
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors : a consensus statement

Peter Nash, Andreas Kerschbaumer, Thomas Doerner, Maxime Dougados, Roy M. Fleischmann, Klaus Geissler, Iain McInnes, Janet E. Pope, Desiree van der Heijde, Michaela Stoffer-Marx, et al.

(2021) ANNALS OF THE RHEUMATIC DISEASES. 80(1). p.71-87
Add to list
- Journal Article
- A1
- open access
Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19 : a meta-analysis

[missing] The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Pere Domingo, Isabel Mur, Gracia María Mateo, Maria del Mar Gutierrez, Virginia Pomar, Natividad de Benito, Noemí Corbacho, Silvia Herrera, Lucia Millan, et al.

(2021) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 326(6). p.499-518
Add to list
- Journal Article
- A1
- open access
Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis : results from the ASAS-COMOSPA study

Carmen Stolwijk, Ivette Essers, Filip Van den Bosch (UGent) , Maxime Dougados, Adrien Etcheto, Désirée van der Heijde, Robert Landewé, Anna Molto, Astrid van Tubergen and Annelies Boonen

(2020) RHEUMATOLOGY. 59(7). p.1632-1639
Add to list
- Journal Article
- A1
- open access
Induction of sustained clinical remission in early axial spondyloarthritis following certolizumab pegol treatment : 48-week outcomes from C-OPTIMISE

Robert Landewe, Desiree van der Heijde, Maxime Dougados, Xenofon Baraliakos, Filip Van den Bosch (UGent) , Karl Gaffney, Lars Bauer, Bengt Hoepken, Natasha de Peyrecave, Karen Thomas, et al.

(2020) RHEUMATOLOGY AND THERAPY. 7(3). p.581-599
Add to list
- Journal Article
- A1
- open access
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

Robert B. M. Landewe, Desiree van der Heijde, Maxime Dougados, Xenofon Baraliakos, Filip Van den Bosch (UGent) , Karl Gaffney, Lars Bauer, Bengt Hoepken, Owen R. Davies, Natasha de Peyrecave, et al.

(2020) ANNALS OF THE RHEUMATIC DISEASES. 79(7). p.920-928
Add to list
- Journal Article
- A1
- open access
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Maxime Dougados, James Cheng-Chung Wei, Robert Landewe, Joachim Sieper, Xenofon Baraliakos, Filip Van den Bosch (UGent) , Walter P. Maksymowych, Joerg Ermann, Jessica A. Walsh, Tetsuya Tomita, et al.

(2020) ANNALS OF THE RHEUMATIC DISEASES. 79(2). p.176-185
Add to list
- Journal Article
- A1
- open access
Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis

Uta Kiltz, Robert B. M. Landewe, Desiree van der Heijde, Martin Rudwaleit, Michael H. Weisman, Nurullah Akkoc, Annelies Boonen, Jan Brandt, Philippe Carron (UGent) , Maxime Dougados, et al.

(2020) ANNALS OF THE RHEUMATIC DISEASES. 79(2). p.193-201
Add to list
- Journal Article
- A1
- open access
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies : 2019 update

Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, Maarten de Wit, Iain McInnes, Maxime Dougados, Jette Primdahl, Dennis G. McGonagle, Daniel Aletaha, Andra Balanescu, et al.

(2020) ANNALS OF THE RHEUMATIC DISEASES. 79(6). p.700-712
Add to list
- Journal Article
- A1
Inequity in biological DMARD prescription for spondyloarthritis across the globe : results from the ASAS-COMOSPA study

Elena Nikiphorou, Desiree van der Heijde, Sam Norton, Robert BM Landewe, Anna Molto, Maxime Dougados, Filip Van den Bosch (UGent) and Sofia Ramiro

(2018) ANNALS OF THE RHEUMATIC DISEASES. 77(3). p.405-411
Add to list
- Journal Article
- A1
Prevalence of comorbidities and risk factors for comorbidities in patients with spondyloarthritis in Latin America : a comparative study with the general population and data from the ASAS-COMOSPA study

Wilson Bautista-Molano, Robert Landewé, Rubén Burgos-Vargas, José Maldonado-Cocco, Anna Moltó, Filip Van den Bosch (UGent) , Rafael Valle-Oñate, Maxime Dougados and Désirée van der Heijde

(2018) JOURNAL OF RHEUMATOLOGY. 45(2). p.206-212
Add to list
- Journal Article
- A1
Work participation in spondyloarthritis across countries : analysis from the ASAS-COMOSPA study

Santiago Rodrigues Manica, Alexandre Sepriano, Sofia Ramiro, Fernando Pimentel Santos, Polina Putrik, Elena Nikiphorou, Sam Norton, Anna Molto, Maxime Dougados, Desiree van der Heijde, et al.

(2018) ANNALS OF THE RHEUMATIC DISEASES. 77(9). p.1303-1310
Add to list
- Journal Article
- A1
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V) : 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Desiree van der Heijde, James Cheng-Chung Wei, Maxime Dougados, Philip Mease, Atul Deodhar, Walter P. Maksymowych, Filip Van den Bosch (UGent) , Joachim Sieper, Tetsuya Tomita, Robert Landewe, et al.

(2018) LANCET. 392(10163). p.2441-2451
Add to list
- Journal Article
- A1
Measurement properties of the ASAS Health Index : results of a global study in patients with axial and peripheral spondyloarthritis

Uta Kiltz, Desiree van der Heijde, Annelies Boonen, Nurullah Akkoc, Wilson Bautista-Molano, Ruben Burgos-Vargas, James Cheng-Chung Wei, Praveena Chiowchanwisawakit, Maxime Dougados, M Tuncay Duruoz, et al.

(2018) ANNALS OF THE RHEUMATIC DISEASES. 77(9). p.1311-1317
Add to list
- Journal Article
- A1
- open access
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target : 2017 update of recommendations by an international task force

Josef S Smolen, Monika Schoels, Juergen Braun, Maxime Dougados, Oliver FitzGerald, Dafna D Gladman, Arthur Kavanaugh, Robert Landewe, Philip Mease, Joachim Sieper, et al.

(2018) ANNALS OF THE RHEUMATIC DISEASES. 77(1). p.3-17
Add to list
- Journal Article
- A1
- open access
The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study

Pauline Bakker, Anna Moltó, Adrien Etcheto, Filip Van den Bosch (UGent) , Robert Landewé, Floris van Gaalen, Maxime Dougados and Désirée van der Heijde

(2017) ARTHRITIS RESEARCH & THERAPY. 19(1).
Add to list
- Journal Article
- A1
Effects of long-term etanercept treatment on clinical outcomes and objective signs of inflammation in early nonradiographic axial spondyloarthritis : 104-week results from a randomized, placebo-controlled study

Maxime Dougados, Désirée van der Heijde, Joachim Sieper, Jürgen Braun, Gustavo Citera, Jan Lenaerts, Filip Van den Bosch (UGent) , James Cheng-Chung Wei, Ron Pedersen, Randi Bonin, et al.

(2017) ARTHRITIS CARE & RESEARCH. 69(10). p.1590-1598

Academic Bibliography

Response to : 'Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis : results of the open-label, pragmatic, cluster-randomised TICOSPA trial' by Cai and Peng response

Goodbye to the term ‘ankylosing spondylitis’, hello ‘axial spondyloarthritis’: time to embrace the ASAS-defined nomenclature

Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis : a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis : results of the open-label, pragmatic, cluster-randomised TICOSPA trial

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors : a consensus statement

Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19 : a meta-analysis

Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis : results from the ASAS-COMOSPA study

Induction of sustained clinical remission in early axial spondyloarthritis following certolizumab pegol treatment : 48-week outcomes from C-OPTIMISE

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies : 2019 update

Inequity in biological DMARD prescription for spondyloarthritis across the globe : results from the ASAS-COMOSPA study

Prevalence of comorbidities and risk factors for comorbidities in patients with spondyloarthritis in Latin America : a comparative study with the general population and data from the ASAS-COMOSPA study

Work participation in spondyloarthritis across countries : analysis from the ASAS-COMOSPA study

Measurement properties of the ASAS Health Index : results of a global study in patients with axial and peripheral spondyloarthritis

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target : 2017 update of recommendations by an international task force

The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study

Effects of long-term etanercept treatment on clinical outcomes and objective signs of inflammation in early nonradiographic axial spondyloarthritis : 104-week results from a randomized, placebo-controlled study

Contents

Support

Contact